Comparative effectiveness of gonadotropins used for ovarian stimulation during assisted reproductive technologies (ART) in France: A real-world observational study from the French nationwide claims database (SNDS).


Journal

Best practice & research. Clinical obstetrics & gynaecology
ISSN: 1532-1932
Titre abrégé: Best Pract Res Clin Obstet Gynaecol
Pays: Netherlands
ID NLM: 101121582

Informations de publication

Date de publication:
Jun 2023
Historique:
received: 25 10 2022
accepted: 19 12 2022
medline: 5 6 2023
pubmed: 28 1 2023
entrez: 27 1 2023
Statut: ppublish

Résumé

This comparative non-interventional study using data from the French National Health Database (Système National des Données de Santé) investigated real-world (cumulative) live birth outcomes following ovarian stimulation, leading to oocyte pickup with either originator recombinant human follicle-stimulating hormone (r-hFSH) products (alfa or beta), r-hFSH alfa biosimilars, or urinaries including mainly HP-hMG (menotropins), and marginally u-hFSH-HP (urofollitropin). Using data from 245,534 stimulations (153,600 women), biosimilars resulted in a 19% lower live birth (adjusted odds ratio (OR) 0.81, 95% confidence interval (CI) 0.76-0.86) and a 14% lower cumulative live birth (adjusted hazard ratio (HR) 0.86, 95% CI 0.82-0.89); and urinaries resulted in a 7% lower live birth (adjusted OR 0.93, 95% CI 0.90-0.96) and an 11% lower cumulative live birth (adjusted HR 0.89, 95% CI 0.87-0.91) versus originator r-hFSH alfa. Results were consistent across strata (age and ART strategy), sensitivity analysis using propensity score matching, and with r-hFSH alfa and beta as the reference group.

Identifiants

pubmed: 36707343
pii: S1521-6934(22)00189-4
doi: 10.1016/j.bpobgyn.2022.102308
pii:
doi:

Substances chimiques

Biosimilar Pharmaceuticals 0
Follicle Stimulating Hormone 9002-68-0
Follicle Stimulating Hormone, Human 0
Gonadotropins 0

Types de publication

Journal Article Observational Study Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

102308

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest MG has received fees from Merck Healthcare KGaA, Darmstadt, Germany, as a medical expert for this study, and lecture fees from Merck KGaA, Darmstadt, Germany, MSD, Ferring, IBSA, Gedeon Richter, Theramex, General Electric, Novartis, Besins Healthcare. I-CD has received fees from Merck Healthcare KGaA, Darmstadt, Germany, as a medical expert for this study, and lecture fees from Merck KGaA, Darmstadt, Germany, MSD, Ferring, IBSA, Gedeon Richter, and Theramex. FR and EH are employees of HEVA, Lyon, France. LL, FP, SP, and CC-B are employees of Merck Santé, Lyon, France, an affiliate of Merck KGaA, Darmstadt, Germany. PV, JES, and TDH are employees of Merck Healthcare KGaA, Darmstadt Germany. CH is an employee of Merck KGaA, Darmstadt Germany. MB has received fees from Merck Healthcare KGaA, Darmstadt, Germany, as a medical expert for this study, and lecture fees from Merck KGaA, Darmstadt, Germany.

Auteurs

M Grynberg (M)

Hôpital Antoine Béclère, Service de Médecine de La Reproduction et Préservation de La Fertilité, 92140, Clamart, France; Hôpital Jean Verdier, Service de Médecine de La Reproduction et Préservation de La Fertilité, 93140, Bondy, France. Electronic address: michael.grynberg@aphp.fr.

I Cedrin-Durnerin (I)

Hôpital Jean Verdier, Service de Médecine de La Reproduction et Préservation de La Fertilité, 93140, Bondy, France. Electronic address: isabelle.cedrin-durnerin@aphp.fr.

F Raguideau (F)

HEVA, 69006 Lyon, France. Electronic address: FRAGUIDEAU@hevaweb.com.

E Herquelot (E)

HEVA, 69006 Lyon, France. Electronic address: eherquelot@hevaweb.com.

L Luciani (L)

Direction des Affaires Médicales - Real-World Evidence, Merck Santé, 69008, Lyon, France. Electronic address: laura.luciani@merckgroup.com.

F Porte (F)

Direction des Affaires économiques - Market Access, Merck Santé, 69008, Lyon, France. Electronic address: fanny.porte@merckgroup.com.

P Verpillat (P)

Merck Healthcare KGaA, Darmstadt, Germany. Electronic address: patrice.verpillat@merckgroup.com.

C Helwig (C)

Merck Healthcare KGaA, Darmstadt, Germany. Electronic address: Christoph.Helwig@merckgroup.com.

J E Schwarze (JE)

Merck Healthcare KGaA, Darmstadt, Germany. Electronic address: juan-enrique.schwarze@merckgroup.com.

S Paillet (S)

Direction des Affaires Médicales - Fertilité, Merck Santé, 69008, Lyon, France. Electronic address: segolene.paillet@merckgroup.com.

C Castello-Bridoux (C)

Direction des Affaires Médicales - Fertilité, Merck Santé, 69008, Lyon, France. Electronic address: claire.castello-bridoux@merckgroup.com.

Thomas D'Hooghe (T)

Merck Healthcare KGaA, Darmstadt, Germany; Department of Development and Regeneration, Laboratory of Endometrium, Endometriosis & Reproductive Medicine, KU Leuven, Herestraat 49 - Box 805 | B-3000, Leuven, Belgium; Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University Medical School, New Haven, CT, 06510, USA. Electronic address: thomas.dhooghe@merckgroup.com.

M Benchaïb (M)

Hôpital Mère Enfant, Service de Médecine de La Reproduction et Préservation de La Fertilité, 69500, Bron, France. Electronic address: mehdi.benchaib@chu-lyon.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH